Katarzyna Drozd1, Ali Ahmadi1, Yupu Deng2, Baohua Jiang2, Julia Petryk1, Stephanie Thorn1, Duncan Stewart2, Rob Beanlands1, Robert A deKemp3, Jean N DaSilva4,5, Lisa M Mielniczuk6. 1. Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada. 2. Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada. 3. Department of Cardiac Imaging, University of Ottawa Heart Institute, Ottawa, ON, Canada. 4. Department of Radiology, Radio-Oncology and Nuclear Medicine, University of Montreal, Montreal, QC, Canada. 5. University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada. 6. Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada. lmielniczuk@ottawaheart.ca.
Abstract
BACKGROUND: Altered myocardial energy metabolism has been linked to worsening of RV function in pulmonary arterial hypertension (PAH). The aim of this study was to evaluate RV glucose and fatty acid metabolism in vivo in a rat model of PAH using positron emission tomography (PET) and investigate the effects of Macitentan on RV substrate utilization. METHODS: PAH was induced in male Sprague-Dawley rats by a single subcutaneous injection of Sugen 5416 (20 mg/kg) followed by 3 weeks of hypoxia (10% oxygen). At week 5 post-injection, the PAH rats were randomized to Macitentan (30 mg/kg daily) treatment or no treatment. Substrate utilization was serially assessed 5 and 8 weeks post-injection with 2-[18F]fluoro-2-deoxyglucose (FDG) and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA) PET for glucose and fatty acid metabolism respectively and correlated with in vivo functional measurements. RESULTS: PAH induction resulted in a 2.5-fold increase in RV FDG uptake (standardized uptake value (SUV) of normal control: 1.6 ± 0.4, week 5: 4.1 ± 1.9, week 8: 4.0 ± 1.6, P < 0.05 for all groups vs. control). RV FTHA showed twofold increased uptake at week 5 (SUV control: 1.50 ± 0.39, week 5: 3.06 ± 1.10, P = 0.03). Macitentan significantly decreased RV FDG uptake at 8 weeks (SUV: 2.5 ± 0.9, P = 0.04), associated with improved RV ejection fraction and reduced RV systolic pressure, while FTHA uptake was maintained. CONCLUSION: PAH is associated with metabolic changes in the RV, characterized by a marked increase in FDG and FTHA uptake. Macitentan treatment reduced PAH severity and was associated with a decrease in RV FDG uptake and improved RV function.
BACKGROUND: Altered myocardial energy metabolism has been linked to worsening of RV function in pulmonary arterial hypertension (PAH). The aim of this study was to evaluate RV glucose and fatty acid metabolism in vivo in a rat model of PAH using positron emission tomography (PET) and investigate the effects of Macitentan on RV substrate utilization. METHODS: PAH was induced in male Sprague-Dawley rats by a single subcutaneous injection of Sugen 5416 (20 mg/kg) followed by 3 weeks of hypoxia (10% oxygen). At week 5 post-injection, the PAH rats were randomized to Macitentan (30 mg/kg daily) treatment or no treatment. Substrate utilization was serially assessed 5 and 8 weeks post-injection with 2-[18F]fluoro-2-deoxyglucose (FDG) and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA) PET for glucose and fatty acid metabolism respectively and correlated with in vivo functional measurements. RESULTS: PAH induction resulted in a 2.5-fold increase in RV FDG uptake (standardized uptake value (SUV) of normal control: 1.6 ± 0.4, week 5: 4.1 ± 1.9, week 8: 4.0 ± 1.6, P < 0.05 for all groups vs. control). RV FTHA showed twofold increased uptake at week 5 (SUV control: 1.50 ± 0.39, week 5: 3.06 ± 1.10, P = 0.03). Macitentan significantly decreased RV FDG uptake at 8 weeks (SUV: 2.5 ± 0.9, P = 0.04), associated with improved RV ejection fraction and reduced RV systolic pressure, while FTHA uptake was maintained. CONCLUSION: PAH is associated with metabolic changes in the RV, characterized by a marked increase in FDG and FTHA uptake. Macitentan treatment reduced PAH severity and was associated with a decrease in RV FDG uptake and improved RV function.
Authors: Hiroshi Ohira; Robert deKemp; Elena Pena; Ross A Davies; Duncan J Stewart; George Chandy; Vladimir Contreras-Dominguez; Carole Dennie; Brian Mc Ardle; Ran Mc Klein; Jennifer M Renaud; Jean N DaSilva; Carolyn Pugliese; Rosemary Dunne; Rob Beanlands; Lisa M Mielniczuk Journal: Eur Heart J Cardiovasc Imaging Date: 2015-06-09 Impact factor: 6.875
Authors: Teemu O Takala; Pirjo Nuutila; Kari Pulkki; Vesa Oikonen; Tove Grönroos; Timo Savunen; Tommi Vähäsilta; Matti Luotolahti; Markku Kallajoki; Jörgen Bergman; Sarita Forsback; Juhani Knuuti Journal: Eur J Nucl Med Mol Imaging Date: 2002-10-03 Impact factor: 9.236
Authors: Marion Hölscher; Katrin Schäfer; Sabine Krull; Katja Farhat; Amke Hesse; Monique Silter; Yun Lin; Bernd J Pichler; Patricia Thistlethwaite; Ali El-Armouche; Lars S Maier; Dörthe M Katschinski; Anke Zieseniss Journal: Cardiovasc Res Date: 2012-01-18 Impact factor: 10.787
Authors: William C Stanley; Eric E Morgan; Hazel Huang; Tracy A McElfresh; Joseph P Sterk; Isidore C Okere; Margaret P Chandler; Jiefei Cheng; Jason R B Dyck; Gary D Lopaschuk Journal: Am J Physiol Heart Circ Physiol Date: 2005-08-12 Impact factor: 4.733
Authors: Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer Journal: J Mol Med (Berl) Date: 2012-12-18 Impact factor: 4.599
Authors: I P Temple; O Monfredi; G Quigley; H Schneider; M Zi; E J Cartwright; M R Boyett; V S Mahadevan; G Hart Journal: Int J Cardiol Date: 2014-10-11 Impact factor: 4.164
Authors: Baktybek Kojonazarov; Stefan Hadzic; Hossein Ardeschir Ghofrani; Friedrich Grimminger; Werner Seeger; Norbert Weissmann; Ralph Theo Schermuly Journal: Am J Respir Crit Care Med Date: 2019-12-01 Impact factor: 21.405
Authors: Anne-Marie C Koop; Guido P L Bossers; Mark-Jan Ploegstra; Quint A J Hagdorn; Rolf M F Berger; Herman H W Silljé; Beatrijs Bartelds Journal: J Am Heart Assoc Date: 2019-10-28 Impact factor: 5.501